Deltex Medical Share Discussion Threads

[the count] 24/9/2018 16:12

--->BUYWELL3

Do you try to deceive people deliberately or are you a prize idiot? Both is most likely the answer.


You claim... 'Accordingly, it does not provide the hospital with the complete solution for the haemodynamic monitoring of all of its patients

In other words ... it has limited use'


Then praytell which haemodynamic company has a greater use?

And tell us why?

Why don't you stop deceiving people by trying to imply that the greater market for DEMG is primarily the awake+intensive care market. This is a red herring and you bloody well know it is.

The major market for DEMG is in the operating theatre.

Why don't you try telling other posters on here how much bigger that market is than the market you are using for your straw man argument? No, let me make it easier for you.... why don't you try telling us how many 100's of percents greater than the market you are fixated on, is the operating theatre market?

And can you inform us, which of the other so called haemodynamic companies have even a single RANDOMISED CLINICAL TRIAL supporting their technologyIN THE OPERATING THEATRE? Just a single one. That shouldn't be too hard for you should it now, oh great sage. Come on, give us just the one.

THE COUNT!

[barman92] 24/9/2018 15:35

Buywell I think you have misunderstood.

A full relevant quote is as follows:

"New product development and the TrueVue System

The Group's initial - and principal - technology is doppler-based oesophageal haemodynamic monitoring. This technology generates highly accurate, real time data; however, it can only be easily used on anesthetised or sedated patients. Accordingly, it does not provide the hospital with the complete solution for the haemodynamic monitoring of all of its patients.

Deltex Medical recently launched its TrueVue System monitoring platform which comprises three haemodynamic monitoring technologies: (i) its existing oesophageal doppler ultrasound (TrueVue Doppler); (ii) high-definition impedance cardiography (TrueVue Impedance); and (iii) pulse pressure waveform analysis (TrueVue PressureWave). The TrueVue System enables the Group to sell its haemodynamic monitoring technologies into a larger addressable market within a given hospital.

The TrueVue System is currently available in the UK, continental Europe and a number of other international markets. 510(k) regulatory clearance has now been obtained from the US Food & Drug Administration (FDA) to market the TrueVue System in the USA, with product launches planned for 2019.

In general terms there is a trade-off between the ease-of-use and the precision of the data generated from each monitoring technology. The TrueVue platform enables clinicians to match the appropriate technology to the risk profile of the patients as they move through the hospital. For example, high-risk, anaesthetised patients undergoing surgery can be treated under the guidance of the extremely precise TrueVue Doppler, whereas lower-risk, awake patients in a high dependency unit can be monitored using non-invasive TrueVue Impedance."

So the "new TrueVue system product" to which you refer can be used on non-sedated patients, using the Impedance and / or PressureWave technologies.

[buywell3] 24/9/2018 15:12

If Mr Keen had not been buying

DEMG would now IMO be 0.25p or less

It remains to see who has now sold around 65M shares in the last month or so


As it is now , the new TrueVue system product can only be easily used on anesthetised or sedated patients.

Accordingly, it does not provide the hospital with the complete solution for the haemodynamic monitoring of all of its patients

In other words ... it has limited use





From the results today

Operational highlights

''-- Focus on developing relationships with existing customers also expected to help the generation of incremental revenues from new TrueVue System product launches''


''it can only be easily used on anesthetised or sedated patients. Accordingly, it does not provide the hospital with the complete solution for the haemodynamic monitoring of all of its patients.''

[dj trading] 24/9/2018 14:41

"mrC2u24 Sep '18 - 10:36 - 9580 of 9582
Hmmm. £158k a month is a lot. BUT this includes >£500k of reductions in creditors"

Arf - You appear to have overlooked other working capital items - receivables down £564k and stock down £47k. Perhaps you picked your number up from the text - which I don't read as all that matters is Revenue and Cashburn at this stage

I have added Rev to my cashburn analysis which is important given the high GM they achieve
Either 1H 18 was a poor half for Rev or they are going to struggle to reduce burn on significantly reduced Rev
dyor etc.

Monthly cash burn
(Movement in cash balance + financing)

2010 Rev £6.3m Burn £95k/month
2011 Rev £6.3m Burn £157k/month
2012 Rev £6.8m Burn £162k/month
2013 Rev £7.2m Burn £197k/month
2014 Rev £6.5m Burn £220k/month
2015 Rev £6.4m Burn £180k/month
2016 Rev £6.3m Burn £198k/month
2017 Rev £5.9m Burn £102k/month
1H18 Rev £2.3m Burn £158k/month
dyor

[janatha] 24/9/2018 14:11

Still very happy to be in at these levels. If it drops much to 1p or lower will top up. After Nigel Keen topped up there was unlikely to be any dramatic news short term or he might have been done for insider training. He has bought just because he fundamentally believes the company is undervalued.
It has taken a massive amount of time and investment (and losses) to create their tried and tested technology with glowing reviews. A great deal of the attraction of DM for me is they have created a formidable moat around the company which would take the aforementioned time and investment to recreate - why would anyone bother? (you may say why would anyone go through all that to be still making hefty losses!)
It has been a source of great frustration that the forecast strong sales and break even have failed to materialise. I can understand how some long term shareholders have thrown in the towel. However, the new reality is incremental growth and absolute focus on break even, maybe even at the expense of some future sales gains. When the company breaks into profit then more of the focus can be put back again on sales growth. When, and only when, the company breaks into profit the share price will go on an upward trajectory.

[arf dysg] 24/9/2018 13:13

mrC2u, sounds good.

redundancies are a mix of good and bad... let's assume (hope!!!) that they still have enough staff to produce probes.

...including, of course, the K9 probe and the TARDIS monitor.

[mrc2u] 24/9/2018 10:36

DJHmmm. £158k a month is a lot. BUT this includes >£500k of reductions in creditors and over £250k in redundancies & pay-offs. Seem to remember the old CEO saying they had stretched creditors by £0.5m prior to fundraising so looks realIf you take these out then underlying burn down to c £30k a month BEFORE another £80k or more a month of additional cost reductions. I make that £50k a month positive even with rubbish sales. And they sound quite positive on salesIf I have got that right, then they don't ever need more cash and are hugely undervaluedThoughts pleaseMrC

[buywell3] 24/9/2018 09:33

From the results today

Operational highlights

''-- Focus on developing relationships with existing customers also expected to help the generation of incremental revenues from new TrueVue System product launches''


''it can only be easily used on anesthetised or sedated patients. Accordingly, it does not provide the hospital with the complete solution for the haemodynamic monitoring of all of its patients.''



Re ODM and its limited use , this is why I posted


buywell3
1 May '18 - 10:09 - 9337 of 9578 Edit
0   0  0



''Clinical experts report that in conscious patients, movement can make focusing an adequate doppler signal difficult for the operator.

The External Assessment Centre considered that the data submitted for Medical technologies assessment report summary –

CardioQ-ODM conscious patients was not sufficiently robust to support the use of CardioQ-ODM in these patients. ''

CONFIDENTIAL
Page 7 of 70

Description of problem 1.2, 4.1.1, 4.1.6, 7.3.
The references to awake use tend to suggest that the application is distinct in terms of proof of outcomes.

This is not the case.

“Evidence in the submission is weak to support the use of CardioQ-ODM in awake patients.”
“Information submitted by Deltex Medical on awake patients is not sufficiently robust to support the use of
CardioQ-ODM in awake patients”


EAC’s response ( External Assessment Centre)

''The EAC contacted three clinical experts for their opinions.

Two answered that in awake patients it is difficult, due to patient movement, to focus an acceptable
ODM trace.
Two report that patients vary in their tolerance, one adding that tolerance may be easier when the probe is inserted under anaesthesia but remains in place when the patient is awake.

The EAC has made minor revision to the wording in its report on pages 8, 29 and 34 but we stand by
our view that we‟ve correctly summarised the quality of the evidence.


IMO the above is why the NHS sales have dropped over the years and continue to do so

[dj trading] 24/9/2018 09:31

Monthly cash burn
(Movement in cash balance + financing)

2010 £95k/month
2011 £157k/month
2012 £162k/month
2013 £197k/month
2014 £220k/month
2015 £180k/month
2016 £198k/month
2017 £102k/month
1H18 £158k/month
dyor

[catch007] 24/9/2018 09:24

Results were appalling as I expected. A further last ditch fund raising almost certainly ahead creating further dilution to prolong the shareholder agony. I am uncertain how DEMG can describe its product system as world class when it clearly is losing traction in its target markets. The moron ramper who recently posted it is a 'stunning business' should read the results again and again as there is nothing to suggest this is the case.

[chrisdgb] 24/9/2018 09:16

Frustrating reaction this morning but happy the recovery story is in place and good the CEO has taken the axe to costs.......

[buywell3] 24/9/2018 07:19

Over 126M shares traded since mid July

Should be some RNS's now to say who has been selling

From the results

Operational highlights

''-- Focus on developing relationships with existing customers also expected to help the generation of incremental revenues from new TrueVue System product launches''


''it can only be easily used on anesthetised or sedated patients. Accordingly, it does not provide the hospital with the complete solution for the haemodynamic monitoring of all of its patients.''







buywell3 - 25 Jul 2018 - 14:08:47 - 9442 of 9576 Deltex Medical - a British success story! - DEMG
FWIW

With the current share price now sub one penny and with many annual cash raising events behind it , going back years

It is only the olde bull brigade with shares garnered at 30p or so , that never sold , that still believe and buy today.

Another loss of $2M looks very likely

Therefore the 1M cash left will need replacing in around 6 months

With falling sales everywhere , and the share price approaching 0.8p , the next raise price would surely have to be 0.5p

Which means to raise £2M ... to give this a chance to live another 12 months

ie Another 400 Million shares sold , and with loan notes , the Billion shares mark gets hit

[opodio] 24/9/2018 07:16

not much cash left

redundancies absorbed most of the cash
-- Operating loss (before exceptional costs) of GBP999,000 (2017 H1: GBP1,082,000)


needs a placing quick


I make it only 5 months cash remaining here

[buywell3] 24/9/2018 07:14

From the results

Operational highlights

''-- Focus on developing relationships with existing customers also expected to help the generation of incremental revenues from new TrueVue System product launches''


''it can only be easily used on anesthetised or sedated patients. Accordingly, it does not provide the hospital with the complete solution for the haemodynamic monitoring of all of its patients.''


From the results

New product development and the TrueVue System

The Group's initial - and principal - technology is doppler-based oesophageal haemodynamic monitoring. This technology generates highly accurate, real time data; however, it can only be easily used on anesthetised or sedated patients. Accordingly, it does not provide the hospital with the complete solution for the haemodynamic monitoring of all of its patients.

[mrc2u] 23/9/2018 12:31

Interesting indeed even if entirely fake! What about Hambro who have even said they have been selling?

[buywell3] 23/9/2018 07:41

Over 120M shares in DEMG have been traded since Aug15th

ie over 60M sells , 60 M buys

info can be checked



IMO this will most likely be these Institutions selling

Henderson Global Investors Ltd.
AS OF 02 MAR 2018
25.00m 5.07%

Herald Investment Management Ltd.
AS OF 09 OCT 2017
23.36m 4.74%

Reyker Securities Plc
AS OF 02 JUL 2018
12.49m 2.54%

Add these up and you get 60.85M shares which again IMO looks about right

Interesting

[babbler] 21/9/2018 15:35

Big trades both ways so who knows... Being controlled probably.

[arf dysg] 21/9/2018 15:07

msufi77 (9555) "big blue day tommorows 2-3p coming for y"

The first rule of the market is "The stock market's a funny place."
The second rule is "The stock market never does what you expect it to."

You could try to bluff the market by expecting it to go down, hoping that that will make it go up, but the market will then find a new and interesting way to crush your dreams.


I'm still waiting for the combined flesh-eating horrors set to Caribbean music. That's the zombie apocalypso.

[babbler] 21/9/2018 12:34

Then again... Who knows. In loss now so in for Monday. See what happens.

[babbler] 21/9/2018 09:37

Looking at the nice round buys I'd say it's possible

[chrisdgb] 21/9/2018 07:37

Hoping that Monday's results deliver some clarity........

[babbler] 20/9/2018 14:44

Yup. Low volume as no one wants to sell and none to buy.

[msufi77] 20/9/2018 13:20

nt trade only

[ramnik007] 20/9/2018 08:44

Notice share price going up since publication of this on 11th Sept : hxxps://www.deltexmedical.com/news/improving-safety-through-patient-monitoring/